juzo dynamic class 2 (23-32mmhg) below knee closed toe with silicone top band lymphoedema garment extra short size i
23-32mmhg) below knee closed toe with silicone top band lymphoedema garment extra short size i blueberry (juzo uk ltd -
juzo dynamic class 2 (23-32mmhg) below knee closed toe with silicone top band lymphoedema garment extra short size ii
23-32mmhg) below knee closed toe with silicone top band lymphoedema garment extra short size ii blueberry (juzo uk ltd -
juzo dynamic class 2 (23-32mmhg) below knee closed toe with silicone top band lymphoedema garment extra short size iii
23-32mmhg) below knee closed toe with silicone top band lymphoedema garment extra short size iii blueberry (juzo uk ltd -
juzo dynamic class 2 (23-32mmhg) below knee closed toe with silicone top band lymphoedema garment extra short size iv
23-32mmhg) below knee closed toe with silicone top band lymphoedema garment extra short size iv blueberry (juzo uk ltd -
juzo dynamic class 2 (23-32mmhg) below knee closed toe with silicone top band lymphoedema garment extra short size v
23-32mmhg) below knee closed toe with silicone top band lymphoedema garment extra short size v blueberry (juzo uk ltd -
juzo dynamic class 2 (23-32mmhg) below knee closed toe with silicone top band lymphoedema garment extra short size vi
23-32mmhg) below knee closed toe with silicone top band lymphoedema garment extra short size vi blueberry (juzo uk ltd -
betaloc cr 23.75
astrazeneca limited - metoprolol succinate 23.75mg; - modified release tablet - 23.75 mg - active: metoprolol succinate 23.75mg excipient: ethylcellulose hydrated silica hyprolose hypromellose liquid paraffin macrogol 6000 microcrystalline cellulose sodium stearyl fumarate titanium dioxide - · hypertension. to reduce blood pressure and to reduce the risk of cardiovascular and coronary mortality (including sudden death), and morbidity. · angina pectoris. · symptomatic mild to severe chronic heart failure as an adjunct to other heart failure therapy to: increase survival, reduce hospitalisation, improve left ventricular function, improve new york heart association (nyha) functional class and improve quality of life. · cardiac arrhythmias, especially supraventricular tachycardia, reduction of ventricular rate in atrial fibrillation and ventricular extrasystoles. · maintenance treatment after myocardial infarction · hyperthyroidism. · functional heart disorder with palpitations. · migraine prophylaxis. · paediatric hypertension
voltarol 12 hour emulgel p 2.32% gel
haleon uk ltd - diclofenac diethylammonium - cutaneous gel - 23.2mg/1gram
23-valent pneumococcal polysaccharide vaccine injection
23-valent pneumococcal polysaccharide vaccine - injection - 0.5ml/dose/syringe which consists of 23 serotypes - vaccines
pneumovax 23 vaccine
merck sharp & dohme (new zealand) limited - pneumococcal polysaccharide vaccine 50 µg/ml (25mcg/dose of each of 23 named pneumococcal polysaccharides) - solution for injection - active: pneumococcal polysaccharide vaccine 50 µg/ml (25mcg/dose of each of 23 named pneumococcal polysaccharides) excipient: phenol sodium chloride water for injection - pneumovax 23 is indicated for vaccination against pneumococcal disease caused by those pneumococcal types included in the vaccine.